WARNING HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY Hepatitis B virus (HBV) reactivation can occur in patients receiving CD20-directed cytolytic antibodies, includi…+
In the Single-Arm, Multicenter Trial of 154 Patients, Patients With CLL Refractory to Fludarabine and Alemtuzumab (FA) Comprised the Efficacy Population for ARZERRA (n=59)1
Baseline Characteristics for Patients With CLL Refractory to Fludarabine and Alemtuzumab in the Study of ARZERRA (n=59)1
The Patient Population Had Received a Median of 5 Prior Therapies1
When Treated With ARZERRA Monotherapy, 42% of Patients With CLL Refractory to Fludarabine and Alemtuzumab Achieved a Partial Response1
In this presentation, Michael W. Schuster, MD, presents 2 case studies of patients with chronic lymphocytic leukemia. The first case is that of a newly diagnosed patient. The second one is that of a heavily pretreated patient refractory to several lines of therapy. As part of this discussion, Dr Schuster reviews several important aspects, including epidemiology, diagnosis, and assessing for prognostic markers before determining management and treatment decisions for these patients.
In this roundtable presentation, expert panelists Shuo Ma, MD, PhD, Francisco Hernandez-Ilizaliturri, MD, and Michael W. Schuster, MD, present a case of a patient with relapsed/refractory chronic lymphocytic leukemia (CLL). The panelists discuss key considerations for treating refractory CLL in patients who have been heavily pretreated.
This video, presented by Karen Seiter, MD, reviews the efficacy and safety data for ARZERRA® (ofatumumab) in patients with CLL that is refractory to fludarabine and alemtuzumab. Dosing and administration considerations for this patient population are also presented.
1. Arzerra [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2016.
INDICATIONS for ARZERRA® (ofatumumab)
IMPORTANT SAFETY INFORMATION for ARZERRA® (ofatumumab)
Hepatitis B Virus Reactivation
Progressive Multifocal Leukoencephalopathy
Tumor Lysis Syndrome
Most Common Adverse Reactions
*Assessed by a blinded Independent Review Committee (IRC) using the International Workshop on Chronic Lymphocytic Leukemia updated National Cancer Institute–sponsored Working Group (NCI-WG) guidelines (1996).1
The efficacy of ARZERRA was studied in a single-arm, multicenter trial of 154 patients with CLL refractory to fludarabine and alemtuzumab (n=59).1
CI=confidence interval; CLL=chronic lymphocytic leukemia; FA=fludarabine and alemtuzumab.
Reference: 1. Arzerra [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2016.